A groundbreaking blood test may soon predict not only an individual's risk of developing Alzheimer's disease but also the precise year symptoms will begin. Researchers at the Washington University School of Medicine in St. Louis have identified a key protein, p-tau217, in the blood that acts as a biological clock for the disease.
This protein forms "tangles" in the brain, disrupting nerve cell communication. While brain scans can detect these tangles, they are often complex and costly. The new study, published in Nature Medicine, analyzed over 600 older adults and found that p-tau217 levels rise consistently long before memory loss becomes apparent.
By comparing blood samples with cognitive performance, researchers developed a model using age and protein levels to estimate symptom onset with a three-to-four-year margin of error. "We show that a single blood test measuring p-tau217 can provide a rough estimate of when an individual is likely to develop symptoms of Alzheimer’s disease," stated lead author Kellen K. Petersen. Individuals whose p-tau217 levels became abnormal around age 60 experienced symptoms about 20 years later, while those abnormal at age 80 saw symptoms emerge in about 10 years.
Experts suggest this could revolutionize clinical trial design and patient identification for high-risk individuals, potentially enabling earlier interventions. However, researchers caution that the test is still experimental and not yet recommended for cognitively unimpaired individuals for personal medical decisions. Further research with more diverse cohorts and refinement of models are underway, with two large clinical trials exploring whether early treatment with Alzheimer's drugs can benefit those with high protein levels.